Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: J Cardiovasc Pharmacol. 2010 Jan;55(1):67–73. doi: 10.1097/FJC.0b013e3181c37d69

Figure 2. Effect of genetic or pharmacological inhibition of sEH on postischemic contractile function.

Figure 2

a, LVDP recovery at 40min of reperfusion in WT hearts, sEH null, vehicle control and WT treated with t-AUCB (0.1µM). Values represent mean±SEM; n=5–11 per group; *, p<0.05 vs. WT; #, p<0.05 vs. Vehicle control. b, LVDP in perfused hearts from WT, sEH null, vehicle control and WT treated with t-AUCB (0.1µM). Values represent mean ± SEM; n=5–11 per group; *, p<0.05 vs. WT; #, p<0.05 vs. vehicle control.